Secondary hyperparathyroidism - ongoing topical problem of chronic nephropathiesArticles

I. Sotorník, P. Bubeníček, L. Karasová, M. Adamec, M. Kouba, C. Povýšil

Clin Osteol 2003; 8(4): 115-118

1. In chronic dialysis, hyperparathyroidism remains the most significant disorder of bone metabolism.2. Its development is essentially due to a deficiency of 1,25-dihydroxyvitamin D3 and hyperphosphataemia.3. In the context of the discussed issue, calcification and ossification changes in the smooth-muscle cells of the vascular tunica media is a major factor involved in the mortality of dialysed patients.4. Osteoprotegerin as a new regulatory factor has a role not only in regulating the degree of bone turnover, but most probably also in the development of vascular calcifications.5. The preservation of normocalcaemia and normophosphataemia...

The role of calcitriol on bone mineral density in osteopenic women and its relationship to vitamin D receptor gene polymorphismArticles

K. Zajíčková, I. Žofková, M. Hill

Clin Osteol 2003; 8(4): 119-122

The aim of the current prospective study was to evaluate the effect of calcitriol on bone mass in osteopenic women and whether this effect depends on the vitamin D receptor (VDR) gene polymorphisms. Method: The study cohort consists of 35 women (27 of them were postmenopausal, age 68.96 ± 8.85 years) who underwent DXA measurement and were found osteopenic at the lumbar spine (T-score -1.24 ± 0.90) and/or at the hip (T-score -1.39 ± 0.75). All probands received calcitriol (0.25-0.50 pg per day) with calcium (500 mg). Bone mineral density (BMD) was measured at the baseline and during the second year of the treatment. Four single...

The evaluation of bone mineral density and risk factors of osteoporosis in patients with diffuse connective tissue diseasesArticles

M. Žurek, P. Horák, Z. Pospíšil, T. Kraina, L. Kusá, V. Ščudla

Clin Osteol 2003; 8(4): 125-130

This study evaluates the bone mineral density and other risk factors of osteoporosis in the group of 105 patients with autoimmune systemic diseases, 55 females with systemic lupus erythematosus (37 pre-, and 18 postmenopausal), 20 females with systemic sclerosis, 10 patients with dermatomyositis or polymyositis, 20 women with rheumatoid arthritis and in the group of healthy controls. Bone mineral density was measured by the Lunar Prodigy in the area L2-L4, proximal femur, and distal forearm. In the area L2-L4 the osteoporosis was present in 10 %, osteopenia in 30 %, in the hip region os­ teoporosis was found in 5 %, osteopenia in 34 %. In the region...

Effect of transfer factor on biochemical markers of bone turnover and bone mineral density in ovariectomized ratsArticles

J. Rovenský, K. Švík, R. Ištok , M. Stančíková

Clin Osteol 2003; 8(4): 131-134

Transfer factor (TF) is dialyzate of the homogenate of human leucocytes from healthy donors. It contains a mixture of low-molecule biologically acti­ ve substances with molecular weight under 10 kDa. It is used in the treatment of conditions that include disorders of cell-mediated immunity. Based on some theoretical assumptions, as the increase of interferon-Y (IFN-y) in recipients, and some clinical observations, we monitored the effect of TF on biochemical markers of osteoresorption, serum NO and bone mineral density (BMD) in the model of postmenopausal osteoporosis in ovariectomized rats. Our results showed that TF significantly decreases Pyr and...

The role of leptin in bone metabolism - what do we knowArticles

M. Bayer, Š. Kutilek

Clin Osteol 2003; 8(4): 135-137

Leptin is a 14kDa polypeptide, produced by fat cells. Leptin plays a role in signalisation of satiety and inhibition of adipocytes differentiation by nega­ tive feedback. There exists a rich discussion on possible role of leptin in bone metabolism in literature. Leptin is able to induce bone tissue accumula­ tion due to its angiogenic and osteogenic influence on bone cells precursors during fetal period. Leptin reduces bone turnover rate by increasing osteoprotegerin levels in human marrow stromal cells as well as mononuclear cells in mature bone tissue. Leptin directly induces the secretion of interleukin-1 receptor antagonist in human monocytes....

Melatonin - novel regulator of bone?Informations

I. Žofková, K. Zajíčková

Clin Osteol 2003; 8(4): 138-139

Hormone ofthe darkness - melatonin regulates a number ofphysiological processes including biorhytms, sleep, reproduction, neuroendocrine and car­ diovascular functions, respiration, immunity and oncogenesis. Melatonin is produced in pineal gland and in bone marrow cells as well. Thus melato­ nin can modulate bone metabolism in a paracrine way. The recent investigations have suggested that melatonin positively influenced bone remodeling most probably directly at the level of specific receptors localized at the bone cells. Melatonin stimulates bone formation and synthesis of procollagen type I and inhibits bone resorption via the TRANCE axis (RANK and...

Minutes of the Committee meeting of the Society for metabolic bone diseasesInformations

Clin Osteol 2003; 8(4): 140-142

CONGRESS ANNOUNCEMENTSInformations

Clin Osteol 2003; 8(4): 143

INSTRUCTIONS TO AUTTORSInformations

Clin Osteol 2003; 8(4): 144